Skip to main content

Coronavirus (COVID-19): Latest Updates | Visitation PoliciesVisitation PoliciesVisitation PoliciesVisitation PoliciesVisitation Policies | COVID-19 Testing | Vaccine InformationVaccine InformationVaccine Information

Explore URMC
menu

Chunkit Fung, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-0394

Office: (585) 275-5823

Fax: (585) 273-1042

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Locations

James P. Wilmot Cancer Center
601 Elmwood Ave
Rochester, NY 14642

Faculty Appointments

Patient Care Settings

Cancer, Hospital Medicine

Biography

I chose this specialty because of the many exciting new therapeutic options for patients with genitourinary cancers, as well as the opportunity to become an integral part of a team that cares for patients during one of their most difficult times.

As my patient, you can depend on me for compassion and dedication, in addition to an innovative and patient-centered approach to care. My research interests are clinical trials for genitourinary cancers and cancer survivorship research. During my free time, I enjoy running, hiking, cooking and travel.

Conditions I Treat

- Prostate cancer
- Bladder cancer
- Testicular cancer
- Kidney cancer
- Adrenal cancer

Professional Background

Dr. Chunkit Fung graduated Summa Cum Laude with Distinction in Research from Cornell University in 2000. He then went on to Medical School at the University of Pennsylvania in Philadelphia, PA and graduated with his M.D in 2004. He completed his internal medicine Internship and Residency from 2004 through 2007 at the Hospital of the University of Pennsylvania. He held the position of Instructor in the Department of Medicine from the University of Pennsylvania from 2007 to 2008 and subsequently completed his Fellowship in Hematology and Oncology at the Hospital of the University of Pennsylvania from 2008 to 2011. He also received a Master in Clinical Epidemiology in 2012 from the University of Pennsylvania School in Medicine. In July 2011, he came to the University of Rochester School of Medicine and Dentistry as an Assistant Professor in the Department of Hematology and Oncology. His clinical research interests are developing clinical trials to evaluate new therapies in Genitourinary Oncology and Cancer Survivorship Research.

Research

I am a medical oncologist specialized in genitourinary malignancy and an Assistant Professor of medicine with research interests in cancer control, particularly in the development, implementation, and dissemination of mHealth behavioral interventions to prevent and manage treatment- and cancer-related toxicities in cancer survivors, with a specific focus in cardiovascular complications from cancer treatment. Additionally, I am interested in developing clinical trials to evaluate new therapeutics for treatment of urologic malignancies.

Credentials

Specialties

    Education

    2004
    MD | University of Pennsylvania School of Medicine

    Post-doctoral Training & Residency

    07/01/2008 - 06/01/2011
    Fellowship in Hematology & Oncology at Hospital of the University of Pennsylvania GME

    07/01/2006 - 06/30/2007
    Residency in Internal Medicine at Hospital of the University of Pennsylvania GME

    06/01/2004 - 06/30/2006
    Internship in Internal Medicine at Hospital of the University of Pennsylvania GME

    VIEW ALL expand_more

    Awards

    2020
    Human Rights Campaign Leadership Award for Rising Star Gala Leaders

    2019
    Presidential Diversity Award Nominee, University of Rochester

    2018 - 2018
    Civic Leadership Award
    Sponsor: US TOO Prostate Cancer Support Group
    Location: Rochester, NY

    2018
    URMC Wilmot Cancer Institute, Hematology/Oncology Fellowship Training Program, Teacher of the Year 2017/2018

    2016 - 2018
    Empire Clinical Research Investigator Program Fellowship Grant

    2016
    Strong Star Certificate of Appreciation

    2015
    Strong Star Certificate of Appreciation

    2014
    Strong Star Certificate of Appreciation

    2013
    Strong Star Certificate of Appreciation

    2012 - 2015
    Wimot Cancer Center Research Fellowship
    Sponsor: Wimot Cancer Center

    2012
    National Institute of Health Loan Repayment Program Grant
    Sponsor: National Institute of Health (NIH)

    2012
    Patient and Family Centered Care Award

    2012
    Strong Star Certificate of Appreciation

    2011
    American Society of Clinical Oncology Trainee Travel Award
    Sponsor: American Society of Clinical Oncology

    2010
    National Institute of Health Loan Repayment Program
    Sponsor: National Institute of Health

    2010
    NCCN Fellow Recognition Program

    2001
    American Heart Association Cardiovascular Disease and Stroke Fellowship
    Sponsor: American Heart Association

    2000
    Summa Cum Laude with Distinction in Research
    Sponsor: Cornell University

    2000
    Golden Key National Honor Society

    1999
    Howard Hughes Medical Institute Undergraduate Research Scholarship
    Sponsor: Howard Hughes Medical Institute

    1996
    Valedictorian
    Location: Brooklyn Technical High School

    VIEW ALL expand_more

    Clinical Trials

    A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)

    Lead Researcher: Chunkit Fung

    This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy. Each cycle equals 21 days. The dose of atezolizumab is 1200 mg IV flat dose every 3 weeks (Day 1) plus cabozantinib 40 mg orally daily (Day 1 through Day 21). Patients will receive three cycles of treatment prior to cystectomy unless they discontinue treatment for unacceptable toxicity or progressive disease by RECIST v1.1 or withdraw consent.

    View Study Details

    A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

    Lead Researcher: Chunkit Fung

    This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.

    View Study Details

    UGUK17036: Monitoring of Treatment Related Toxicities from Oral Targeted Agents and Immunotherapy Among Patients with Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study.

    Lead Researcher: Chunkit Fung

    To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-related toxicities, quality of life, distress level, and drug adherence.

    View Study Details

    Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

    Lead Researcher: Chunkit Fung

    This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

    View Study Details

    DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

    Lead Researcher: Chunkit Fung

    The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.

    View Study Details

    Publications

    Journal Articles

    3/3/2023
    Clasen SC, Fung C, Sesso HD, Travis LB. "Cardiovascular Risks in Testicular Cancer: Assessment, Prevention, and Treatment." Current oncology reports.. 2023 Mar 3; Epub 2023 Mar 03.

    2/26/2023
    Torous DK, Avlasevich S, Bemis JC, Howard T, Ware RE, Fung C, Chen Y, Sahsrabudhe D, MacGregor JT, Dertinger SD. "Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients." Environmental and molecular mutagenesis.. 2023 Feb 26; Epub 2023 Feb 26.

    2/16/2023
    Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH, . "Rucaparib or Physician's Choice in Metastatic Prostate Cancer." The New England journal of medicine.. 2023 Feb 16; Epub 2023 Feb 16.

    Books & Chapters

    2017
    Chapter Title: Second Cancers
    Book Title: Cancer: Principles & Practice of Oncology, 11th Edition
    Author List: Fung, C., Bhatia, S., Allan, J.M., Oeffinger, K.C., Ng, A., Travis L.B.
    Edited By: DeVita, V.T. Jr., Lawrence, TS., Rosenberg, S.A.
    Published By: Wolters Kluwer Health 2017 in Philadelphia

    2014
    Chapter Title: Second Malignant Neoplasms and Cardiovascular Disease Among Testicular Cancer Survivors
    Book Title: Testicular Cancer: Diagnosis and Clinical Management
    Author List: Fung, C., Fossa SD, Travis LB
    Edited By: Einhorn LH, Horwich A, Huddart R
    Published By: Oxford: Blackwell Publishing 2014

    2014
    Chapter Title: Neurotoxicity and Ototoxicity Among Testicular Cancer Survivors
    Book Title: EAU-ICUD Consultation on Medical Treatment of Urological Malignancies
    Author List: Fung, C., Qi, J, Oldenburg, J
    Edited By: Massard C, Zhou FJ, Fossa SD
    Published By: EAU-ICUD 2014

    VIEW ALL PUBLICATIONS